Rational Pharmacotherapy in Cardiology

Advanced search

Current Guidelines for the Treatment of Arterial Hypertension in Patients with Diabetes Mellitus and Chronic Kidney Disease

Full Text:


The current understanding of the management of patients with diabetes mellitus (DM) based on the concept of the cardiovascular continuum involves not only the prevention and treatment of cardiovascular diseases (CVD), but also the prevention and treatment of chronic kidney disease (CKD). The fact is that patients with DM and CKD represent a special group of patients with a very high risk of CVD and cardiovascular mortality. Such patients require early diagnosis and timely identification of risk factors for the development and progression of CKD for their adequate correction. Arterial hypertension, along with hyperglycemia, is the main risk factor for the development and progression of CKD in patients with diabetes. In this regard, the choice of antihypertensive therapy (AHT) in patients with diabetes is of particular importance. The basis of AHT in diabetes and CKD is the combination of a blocker of the renin-angiotensin-aldosterone system (an angiotensin-converting enzyme inhibitor [ACE inhibitor] or an angiotensin II receptor blocker [ARB]) and a calcium channel blocker (CCB) or a thiazide / thiazide-like diuretic. The task of the performed AHT is to achieve the target level of blood pressure (BP). At the same time, the optimal blood pressure values in patients with diabetes and CKD are blood pressure values in the range of 130-139/70-79 mm Hg. If the target blood pressure is not achieved, it is necessary to intensify antihypertensive therapy by adding a third antihypertensive drug to the therapy: CCB or a diuretic (thiazide / thiazide-like or loop). In case of resistant hypertension, it is necessary to consider the possibility of adding antagonists of mineralocorticoid receptors, other diuretics or alpha-blockers to the conducted AHT. Beta-blockers can be added at any stage of therapy if the patient has exertional angina, a history of myocardial infarction, atrial fibrillation, and chronic heart failure. The need to normalize blood pressure parameters by prescribing combined antihypertensive therapy in patients with diabetes and CKD is explained by a decrease in renal and cardiovascular risks, and, therefore, a decrease in the risk of mortality in this cohort of patients.

About the Authors

T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation

Tatyana Yu. Demidova -  eLibrary SPIN 9600-9796


O. A. Kislyak
Pirogov Russian National Research Medical University
Russian Federation

Oksana A. Kislyak - eLibrary SPIN 3910-6585



1. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 suppl 1):S117-31. DOI:10.1016/s0272-6386(00)70239-3.

2. Moiseev VC, Mukhin NA, Smirnov AV, et al. Cardiovascular risk and chronic kidney disease: cardio- nephroprotection strategies. Russian Journal of Cardiology. 2014;(8):7-37 (In Russ.) DOI:10.15829/1560-4071-2014-8-7-37.

3. Held PJ, Port FK, Webbet RL, et al. Excerpts from United States Renal Data System 1995 Annual Data Report. Am J Kidney Dis. 1995;26(4 Suppl 2):S1-186.

4. Albertus P, Morgenstern H, Robinson B, et al. Risk of ESRD in the United States. Am J Kidney Dis. 2016 Dec;68(6):862-872. DOI:10.1053/j.ajkd.

5. The Renal Association. UK Renal Registry 2014. Available from:

6. Retnakaran R, Cull CA, Thorne RI, et al. for the UKPDS Study Group. Risk Factors for Renal Dysfunction in Type 2 Diabetes. Diabetes. 2006;55(6):1832-9. DOI:10.2337/db05-1620.

7. Shamkhalova MSh, Vikulova OK, Zheleznyakova AV, et al. Epidemiology of chronic kidney disease in the Russian Federation according to the Federal Register of Adult Patients with Diabetes Mellitus (2013-2016). Diabetes Mellitus. 2018;21(3):160-9 (In Russ.) DOI:10.14341/DM9687.

8. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 di-abetes. J Am Soc Nephrol. 2013;24:302-8. DOI:10.1681/ASN.2012070718.

9. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-83. DOI:10.1056/NEJMra054415.

10. Hasslacher C, Ritz E, Wahl P, et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant. 1989;4:859-63. DOI:10.1093/ndt/4.10.859.

11. Mazzucco G, Bertani T, Fortunato M, et al. Different patterns of renal damage in type 2 diabetes mel- litus: A multicentric study on 393 biopsies. Am J Kidney Dis. 2002;39:713-20. DOI:10.1053/ajkd.2002.31988.

12. Amoah E, Glickman JL, Malchoff CD, et al. Clinical identification of nondiabetic renal disease in dia-betic patients with type I and type II disease presenting with renal dysfunction. Am J Nephrol. 1988;8:204-11. DOI:10.1159/000167584.

13. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collabo-ration with the EASD. Eur Heart J. 2020;41(2):255-323. DOI:10.1093/eurheartj/ehz486.

14. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce car-diovascular risk. Eur Heart J. 2019;00:1-78. DOI:10.1093/eurheartj/ehz455

15. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;Suppl 3 (1):1-150. DOI:10.1038/kisup.2012.37.

16. Chronic kidney disease. Clinical guidelines. Association of Nephrologists of Russia (2019). Available from: (In Russ.)

17. Diagnosis and treatment of arterial hypertension in chronic kidney disease. Clinical guidelines. Scientific Society of Nephrologists of Russia, Association of Nephrologists of Russia. Available from: http://nonr. ru/wp-content/uploads/2013/11/Клинические-рекомендации-по-лечению-АГ- при-ХБП-ГЭОТАР-последние.pdf (In Russ.)

18. Microvascular complications and foot care: Standards of medical care in diabetes 2021. Diabetes Care. 2021;44 (Suppl 1):S151-67. DOI:10.2337/dc21-S011.

19. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the man-agement of arterial hypertension of the European Society of Cardiology (ESC) and the European So-ciety of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.

20. Arterial hypertension in adults. Clinical guidelines (2020). Russian Journal of Cardiology. 2020;25(3):37-86 (In Russ.) DOI:10.15829/1560-4071-2020-3-3786.

21. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64:588-97. DOI:10.1016/j.jacc.2014.04.065.

22. Dedov II, Shestakova MV, Mayorov AYu. Algorithms for specialized medical care for patients with di-abetes mellitus. 9th edition. Moscow: Russian Association of Endocrinologists; 2019 (In Russ.) DOI:10.14341/DM221S1.

23. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome in-cidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-44. DOI:10.1097/HJH.0000000000001276.

24. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on di-abetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62. DOI:10.1056/NEJM199311113292004.

25. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensinII receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601-6. DOI:10.1046/j.1523-1755.2000.00880.x.

26. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhi-bition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-61. DOI:10.1056/NEJ-Moa042274.

27. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination ther-apies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespec-ified secondary analysis of a randomized controlled trial. Lancet. 2010;375:1173-81. DOI:10.1016/S0140-6736(09)62100-0.

28. Trukhan DI. Arterial hypertension and chronic heart failure: two targets and one drug - fosinopril. Consilium Medicum. 2018;20(5):50-5 (In RussDOI:10.26442/2075-1753_2018.5.50-55.

29. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens. 2001;19(10):1871-6. doi: 10.1097/00004872200110000-00023.

30. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-31. DOI:10.1001/jama.288.19.2421.

31. Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens. 2004;22(8):1613-22. DOI:10.1097/01.hjh.0000133733.32125.09.

32. Baguet JP, Robitail S, Boyer L, et al. A Meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005;5:131-40. DOI:10.2165/00044011-200727110-00001.

33. Nedogoda SV. Side effects of thiazide diuretics: focus on hypokalemia. Consilium Medicum. 2007;5:77-81 (In Russ.)

34. Patel A, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40. DOI:10.1016/S0140-6736(07)61303-8.

35. Трисветова Е.Л. Нефропротекция ингибитором ангиотензинпревращающего фермента лизиноприлом при артериальной гипертензии. Международные Обзоры: Клиническая Практика и Здоровье 2013;4;85-95.

36. Agardh CD, Garcia-Puig J, Charbonnei В, et al. Greater reduction of urinary albumin excretion in hy-pertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-92.

37. Instructions for medical use of the drug Diroton®. registration number P№011426/01. Available from:Диротон&m=tn (In Russ.)


For citations:

Demidova T.Yu., Kislyak O.A. Current Guidelines for the Treatment of Arterial Hypertension in Patients with Diabetes Mellitus and Chronic Kidney Disease. Rational Pharmacotherapy in Cardiology. 2021;17(2):323-331. (In Russ.)

Views: 337

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)